Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - CCDC6 |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - CCDC6 | intrahepatic cholangiocarcinoma | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) treatment reduced growth of tumoroids derived from a TP53-null intrahepatic cholangiocarcinoma mouse model expressing FGFR2-CCDC6 fusion in culture (PMID: 33741397). | 33741397 | |
FGFR2 - CCDC6 | cholangiocarcinoma | predicted - sensitive | FGFR2 Inhibitor | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase I trial (FIGHT-101), Pemazyre (pemigatinib) treatment led to a partial response lasting 11.3 months in a cholangiocarcinoma patient harboring FGFR2-CCDC6 (PMID: 35176457; NCT02393248). | 35176457 |
FGFR2 - CCDC6 | intrahepatic cholangiocarcinoma | sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment reduced growth of tumoroids derived from a TP53-null intrahepatic cholangiocarcinoma mouse model expressing FGFR2-CCCD6 fusion in culture (PMID: 33741397). | 33741397 |
FGFR2 - CCDC6 | Advanced Solid Tumor | predicted - sensitive | FGFR Inhibitor (Pan) | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2-CCDC6 were sensitive to treatment with Futibatinib (TAS-120) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 - CCDC6 | liver cancer | sensitive | FGFR Inhibitor (Pan) | PRN1371 | Preclinical - Pdx | Actionable | In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of liver cancer harboring FGFR2-CCDC6 fusion (PMID: 28978721). | 28978721 |
FGFR2 - CCDC6 | intrahepatic cholangiocarcinoma | predicted - sensitive | FGFR Inhibitor (Pan) | Futibatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Futibatinib (TAS-120) treatment at a dose of 16mg led to a partial response in 42.1% (8/19) of patients with intrahepatic cholangiocarcinoma harboring FGF or FGFR alterations, including a partial response with a progression-free survival of 6.8 months and a duration of response of 8.8 months in a patient harboring FGFR2-CCDC6 (PMID: 34551969; NCT02052778). | 34551969 |
FGFR2 - CCDC6 | intrahepatic cholangiocarcinoma | predicted - sensitive | FGFR2 Inhibitor | Derazantinib | Case Reports/Case Series | Actionable | In a Phase Ib/II trial, a patient with intrahepatic cholangiocarcinoma harboring FGFR2-CCDC6 demonstrated stable disease when treated with Derazantinib (ARQ 087) (PMID: 30420614; NCT01752920). | 30420614 |
FGFR2 - CCDC6 | Advanced Solid Tumor | predicted - sensitive | FGFR2 Inhibitor | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2-CCDC6 were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 - CCDC6 | intrahepatic cholangiocarcinoma | sensitive | FGFR Inhibitor (Pan) | Infigratinib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) and Mekinist (trametinib) combination treatment synergistically reduced viability of tumoroids derived from a TP53-null intrahepatic cholangiocarcinoma mouse model expressing FGFR2-CCDC6 fusion (PMID: 33741397). | 33741397 |
FGFR2 - CCDC6 | Advanced Solid Tumor | sensitive | FGFR Inhibitor (Pan) | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) inhibited Fgfr phosphorylation and downstream signaling, resulted in growth inhibition of transformed cells expressing FGFR2-CCDC6 in culture (PMID: 28416604). | 28416604 |
FGFR2 - CCDC6 | Advanced Solid Tumor | predicted - sensitive | FGFR Inhibitor (Pan) | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2-CCDC6 were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 - CCDC6 | Advanced Solid Tumor | predicted - resistant | FGFR Inhibitor (Pan) | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2-CCDC6 were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|